Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)
NCT07727538Phase 3Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 3, open-label trial of olezarsen in familial chylomicronemia syndrome (FCS) (2 cohorts), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percent Change from Baseline in Fasting Triglycerides at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
olezarsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT07727538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727538.